Arcus Biosciences RCUS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's EPS (diluted)?
- Arcus Biosciences (RCUS) reported EPS (diluted) of -$1.02 in Q1 2026.
- How has Arcus Biosciences's EPS (diluted) changed year-over-year?
- Arcus Biosciences's EPS (diluted) increased by 10.5% year-over-year, from -$1.14 to -$1.02.
- What is the long-term trend for Arcus Biosciences's EPS (diluted)?
- Over 3 years (2022 to 2025), Arcus Biosciences's EPS (diluted) has grown at a -3.8% compound annual growth rate (CAGR), from -$3.72 to -$3.31.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.